Skip to main content
. 2021 Mar 12;113(9):1203–1211. doi: 10.1093/jnci/djab036

Table 4.

EC risks gBRCA1/2 mutation carriers vs non-BRCA1/2 mutation carriers

Subgroup BRCA1/2 carriers
 non-BRCA1/2 carriers
Total, No. Event, No. Person-years at risk Total, No. Events, No. Person-years at risk HR
(95% CI)a 		P b
Main analysis
 All 5980 58 119 296 8451 33 160 841 2.37 (1.53 to 3.69) <.001
  BRCA1c 3829 44 75 366 8451 33 160 841 2.91 (1.83 to 4.66) <.001
  BRCA2c 2192 14 44 809 8451 33 160 841 1.45 (0.75 to 2.81) .27
 Histologic groups
  Endometrioid 5980 35 119 296 8451 30 160 841 1.61 (0.97 to 2.66) .06
   BRCA1c 3829 27 75 366 8451 30 160 841 2.01 (1.18 to 3.45) .01
   BRCA2c 2192 8 44 809 8451 30 160 841 0.93 (0.41 to 2.11) .86
  Serous-like 5980 19 119 296 8451 3 160 841 8.08 (2.34 to 27.94) .001
   BRCA1c 3829 15 75 366 8451 3 160 841 10.48 (2.95 to 37.20) <.001
   BRCA2c 2192 4 44 809 8451 3 160 841 4.13 (0.83 to 20.50) .08
 Molecular group
   p53-abnormald 5980 27 119 296 8451 3 160 841 11.31 (3.37 to 37.95) <.001
    BRCA1c 3829 23 75 366 8451 3 160 841 15.71 (4.62 to 53.40) <.001
    BRCA2c 2192 4 44 809 8451 3 160 841 4.11 (0.83 to 20.39) .08
Sensitivity analyses
 Start follow-up from date   of gBRCA1/2 DNA testd
  All histotypes 5771 37 56 579 8098 11 48 044 3.26 (1.65 to 6.44) .001
  Endometrioid 5771 22 56 579 8098 10 48 044 2.76 (1.26 to 6.02) .01
  Serous-like 5771 14 56 579 8098 1 48 044 18.28 (2.33 to 143.34) .01
  p53-abnormald 5771 21 56 579 8098 1 48 044 26.64 (3.51 to 202.32) .01
  BRCA1, all histotypesc 3700 29 37 984 8098 11 48 044 5.57 (2.69 to 11.54) <.001
  BRCA2, all histotypesc 2108 8 18 971 8098 11 48 044 2.18 (0.80 to 5.91) .13
 Additional censoring HT-BCf
  All 5966 50 113 033 8447 30 155 002 2.30 (1.44 to 3.66) <.001
  Endometrioid 5966 32 113 033 8447 28 155 002 1.56 (0.93 to 2.64) .09
  Serous-like 5966 14 113 033 8447 2 155 002 8.78 (1.94 to 39.65) .01
  p53-abnormald 5966 22 113 033 8447 2 155 002 13.62 (3.15 to 59.00) <.001
  BRCA1, all histotypesc 3821 37 72 423 8447 30 155 002 2.61 (1.58 to 4.31) <.001
  BRCA2, all histotypesc 2186 13 41 461 8447 30 155 002 1.60 (0.82 to 3.12) .17
a

All hazard ratios were adjusted for age. BC = breast cancer; CI = confidence interval; DCIS = ductal carcinoma in situ; EC = endometrial cancer; FFPE = formalin fixed paraffin embedded; HR = hazard ratio; HT = hormone treatment.

b

The P values assessing the null hypothesis of hazard ratio = 1.00.

c

Women with both a gBRCA1 and a gBRCA2 mutation were included in both analyses stratified for gBRCA1/2 mutation status.

d

Includes cases for which p53-status was unknown (no FFPE tumor block available) and for whom p53-status was based on most common p53-status for the histotype as described in the material and methods. When excluding cases for which p53-status was based on histotype, the number of events remained the same for gBRCA1/2 carriers, but only 2 events occurred in the non-gBRCA1/2 mutation carriers (HR = 17.07, 95% CI = 4.0 to 72.8, P < .001).

e

If the date of gBRCA1/2-DNA test was unknown, this date was considered to be January 1, 1995.

f

DCIS was considered as BC. If a woman developed a BC or DCIS for which HT status was unknown, the date of diagnoses was not considered as censoring event.